Barclays kept an overweight on PTC Inc. (NASDAQ:PTC) while trimming its price target to $150, as the company secures a notable win supplying Creo CAD for a Haifa Digital Implant Engineering Center to enable digital design and metal 3D printing of patient-specific implants with Rambam and EOS.
Previous Week Recap
- Barclays Maintains Overweight, Lowers PT: Barclays kept an overweight on PTC Inc. (PTC) and cut its price target to $150 from $185, per a 12:54 GMT analyst note.
- PTC To Supply Creo For Implants: PTC (PTC) will supply Creo CAD for a Haifa Digital Implant Engineering Center, enabling digital design and metal 3D printing of patient-specific implants alongside Rambam and EOS.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.